Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Blood (2024) 144 (15): 1595–1610.

https://doi.org/10.1182/blood.2023022884

Published: 2024

Includes: Supplemental data

Journal Articles

A lineage-specific STAT5B N642H mouse model to study NK-cell leukemia

Klara Klein, Sebastian Kollmann, Angela Hiesinger, Julia List, Jonatan Kendler, Thorsten Klampfl, Mehak Rhandawa, Jana Trifinopoulos, Barbara Maurer, Reinhard Grausenburger, Christof A. Betram, Richard Moriggl, Thomas Rülicke, Charles G. Mullighan, Agnieszka Witalisz-Siepracka, Wencke Walter, Gregor Hoermann, Veronika Sexl, Dagmar Gotthardt

Blood (2024) 143 (24): 2474–2489.

https://doi.org/10.1182/blood.2023022655

Published: 2024

Includes: Supplemental data

Journal Articles

A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells

Sebastian Kollmann, Reinhard Grausenburger, Thorsten Klampfl, Michaela Prchal-Murphy, Klavdija Bastl, Hanja Pisa, Vanessa M. Knab, Tania Brandstoetter, Eszter Doma, Wolfgang R. Sperr, Sabine Lagger, Matthias Farlik, Richard Moriggl, Peter Valent, Florian Halbritter, Karoline Kollmann, Gerwin Heller, Barbara Maurer, Veronika Sexl

Blood (2021) 138 (23): 2347–2359.

https://doi.org/10.1182/blood.2021010980

Published: 2021

Includes: Supplemental data

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Blood (2017) 130 (23): 2499–2503.

https://doi.org/10.1182/blood-2017-05-785683

Published: 2017

Includes: Supplemental data

Journal Articles

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Karoline V Gleixner, MD, Mathias A Schneeweiss, MD, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Daniela Berger, Gregor Eisenwort, MD PhD, Georg Greiner, MD, Konstantin Byrgazov, PhD, Gregor Hoermann, Marina Konopleva, MD PhD, Islam Waliul, Patrick T Gunning, PhD, Hiroshi Maeda, PhD, Richard Moriggl, PhD, Michael W. Deininger, MD PhD, Thomas Lion, PhD, Michael Andreeff, MD PhD, Peter Valent, MD

Blood (2016) 128 (22): 4241.

https://doi.org/10.1182/blood.V128.22.4241.4241

Published: 2016

Journal Articles

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Ira L. Kraft, BS, Brent D.G. Page, PhD, Tian Y. Zhang, MD, PhD, Jamshid S. Khorashad, MD, PhD, FRCPath, Nadeem A. Vellore, PhD, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna V. Senina, MS, Matthew S. Zabriskie, BS, Shazia Ahmad, Clinton C. Mason, PhD, Richard Moriggl, PhD, Riccardo Baron, PhD, Thomas O'Hare, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2013) 122 (21): 854.

https://doi.org/10.1182/blood.V122.21.854.854

Published: 2013

Journal Articles

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Anna M. Eiring, PhD, Ira L Kraft, BS, Brent DG Page, BS, David J Anderson, BA, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Matthew S Zabriskie, BS, Richard Moriggl, PhD, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 31.

https://doi.org/10.1182/blood.V120.21.31.31

Published: 2012

Journal Articles

TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia

Blood (2012) 120 (21): 1470.

https://doi.org/10.1182/blood.V120.21.1470.1470

Published: 2012

Journal Articles

Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,

Harini Nivarthi, Andriy Tsyrulnyk, Wolfgang Warsch, Zhengqi Wang, Susanne Winkler, Lukas Kenner, MD, Mathias Müller, DVM, Christopher Baum, MD, Kevin D. Bunting, PhD, Veronika Sexl, MD, Thomas Rülicke, D.V.M., Richard Moriggl, PhD

Blood (2011) 118 (21): 3399.

https://doi.org/10.1182/blood.V118.21.3399.3399

Published: 2011

Journal Articles

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart, Sabine Fajmann, Sabine Cerny-Reiterer, Andrea Hölbl, Karoline V. Gleixner, Michael Dworzak, Matthias Mayerhofer, Gregor Hoermann, Harald Herrmann, Christian Sillaber, Gerda Egger, Peter Valent, Richard Moriggl, Veronika Sexl

Blood (2011) 117 (12): 3409–3420.

https://doi.org/10.1182/blood-2009-10-248211

Published: 2011

Includes: Supplemental data

Journal Articles

Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia

Takaomi Sanda, MD, PhD, Jeffrey W Tyner, PhD, Alejandro Gutierrez, MD, Vu N Ngo, PhD, Richard Moriggl, Yebin Ahn, Jason M Glover, MD, Bill H Chang, MD, PhD, Stephanie G Willis, Louis M. Staudt, MD, PhD, Brian J Druker, MD, A. Thomas Look, MD

Blood (2010) 116 (21): 3155.

https://doi.org/10.1182/blood.V116.21.3155.3155

Published: 2010

Journal Articles

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation

Katrin Friedbichler, Marc A. Kerenyi, Boris Kovacic, Geqiang Li, Andrea Hoelbl, Saliha Yahiaoui, Veronika Sexl, Ernst W. Müllner, Sabine Fajmann, Sabine Cerny-Reiterer, Peter Valent, Hartmut Beug, Fabrice Gouilleux, Kevin D. Bunting, Richard Moriggl

Blood (2010) 116 (9): 1548–1558.

https://doi.org/10.1182/blood-2009-12-258913

Published: 2010

Includes: Supplemental data

Journal Articles

STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease

Geqiang Li, Kristy L. Miskimen, Zhengqi Wang, Xiu Yan Xie, Jennifer Brenzovich, John J. Ryan, William Tse, Richard Moriggl, Kevin D. Bunting

Blood (2010) 115 (7): 1416–1424.

https://doi.org/10.1182/blood-2009-07-234963

Published: 2010

Includes: Supplemental data

Journal Articles

Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model.

Geqiang Li, Ph.D., Zhengqi Wang, Ph.D., Kristy L. Miskimen, Ph.D., Xiu Yan Xie, M.D., William Tse, M.D., Fabrice Gouilleux, Ph.D., Richard Moriggl, Ph.D., Kevin D. Bunting, Ph.D.

Blood (2009) 114 (22): 3902.

https://doi.org/10.1182/blood.V114.22.3902.3902

Published: 2009

Journal Articles

The Src Kinases Play a Crucial Role in the Growth of Hematopoietic Cells Transformed with Constitutively Activated Stat5 Mutants.

Remy Nyga, Fabrice Gouilleux, Ph.D., Flora Cartier, Christian Pecquet, Aline Regnier, Jean-Pierre Marolleau, Jacques Rochette, Richard Moriggl, Ph.D., Hicham Bouhlal, Kaiss Lassoued

Blood (2009) 114 (22): 5041.

https://doi.org/10.1182/blood.V114.22.5041.5041

Published: 2009

Journal Articles

STAT5 Requires the N-Domain for Suppression of miR15/16, Induction of Bcl-2, and Survival Signaling in Myeloproliferative Disease.

Geqiang Li, Ph.D., Kristy L. Miskimen, Ph.D., Zhengqi Wang, Ph.D., Xiu Yan Xie, M.D., Jennifer Brenzovich, B.S., John J Ryan, Ph.D., William Tse, M.D., Richard Moriggl, Ph.D., Kevin D. Bunting, Ph.D.

Blood (2009) 114 (22): 211.

https://doi.org/10.1182/blood.V114.22.211.211

Published: 2009

Journal Articles

Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1

Marc A. Kerenyi, Florian Grebien, Helmuth Gehart, Manfred Schifrer, Matthias Artaker, Boris Kovacic, Hartmut Beug, Richard Moriggl, Ernst W. Müllner

Blood (2008) 112 (9): 3878–3888.

https://doi.org/10.1182/blood-2008-02-138339

Published: 2008

Includes: Supplemental data

Journal Articles

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

Noria Harir, Cédric Boudot, Katrin Friedbichler, Karoline Sonneck, Rudin Kondo, Séverine Martin-Lannerée, Lukas Kenner, Marc Kerenyi, Saliha Yahiaoui, Valérie Gouilleux-Gruart, Jean Gondry, Laurence Bénit, Isabelle Dusanter-Fourt, Kaïss Lassoued, Peter Valent, Richard Moriggl, Fabrice Gouilleux

Blood (2008) 112 (6): 2463–2473.

https://doi.org/10.1182/blood-2007-09-115477

Published: 2008

Includes: Supplemental data

Journal Articles

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2

Florian Grebien, Marc A. Kerenyi, Boris Kovacic, Thomas Kolbe, Verena Becker, Helmut Dolznig, Klaus Pfeffer, Ursula Klingmüller, Mathias Müller, Hartmut Beug, Ernst W. Müllner, Richard Moriggl

Blood (2008) 111 (9): 4511–4522.

https://doi.org/10.1182/blood-2007-07-102848

Published: 2008

Includes: Supplemental data

NARROW

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

A lineage-specific STAT5B N642H mouse model to study NK-cell leukemia

A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia

Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation

STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease

Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model.

The Src Kinases Play a Crucial Role in the Growth of Hematopoietic Cells Transformed with Constitutively Activated Stat5 Mutants.

STAT5 Requires the N-Domain for Suppression of miR15/16, Induction of Bcl-2, and Survival Signaling in Myeloproliferative Disease.

Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only